These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28192639)

  • 1. A deep learning based strategy for identifying and associating mitotic activity with gene expression derived risk categories in estrogen receptor positive breast cancers.
    Romo-Bucheli D; Janowczyk A; Gilmore H; Romero E; Madabhushi A
    Cytometry A; 2017 Jun; 91(6):566-573. PubMed ID: 28192639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    Whitney J; Corredor G; Janowczyk A; Ganesan S; Doyle S; Tomaszewski J; Feldman M; Gilmore H; Madabhushi A
    BMC Cancer; 2018 May; 18(1):610. PubMed ID: 29848291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated Tubule Nuclei Quantification and Correlation with Oncotype DX risk categories in ER+ Breast Cancer Whole Slide Images.
    Romo-Bucheli D; Janowczyk A; Gilmore H; Romero E; Madabhushi A
    Sci Rep; 2016 Sep; 6():32706. PubMed ID: 27599752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
    Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
    Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
    Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
    Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
    Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.
    Li H; Whitney J; Bera K; Gilmore H; Thorat MA; Badve S; Madabhushi A
    Breast Cancer Res; 2019 Oct; 21(1):114. PubMed ID: 31623652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.
    Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S
    Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.